Esteban F, Ramos-Garcia P, Munoz M, Gonzalez-Moles M
Int J Environ Res Public Health. 2022; 19(1).
PMID: 35010633
PMC: 8751191.
DOI: 10.3390/ijerph19010375.
Aczel T, Kecskes A, Kun J, Szenthe K, Banati F, Szathmary S
Int J Mol Sci. 2020; 21(8).
PMID: 32331300
PMC: 7215309.
DOI: 10.3390/ijms21082938.
Ashina M, Hansen J, Do T, Melo-Carrillo A, Burstein R, Moskowitz M
Lancet Neurol. 2019; 18(8):795-804.
PMID: 31160203
PMC: 7164539.
DOI: 10.1016/S1474-4422(19)30185-1.
Jensen D, Lieu T, Halls M, Veldhuis N, Imlach W, Mai Q
Sci Transl Med. 2017; 9(392).
PMID: 28566424
PMC: 6034632.
DOI: 10.1126/scitranslmed.aal3447.
Zhou J, Ling J, Song H, Lv B, Wang L, Shang J
Oncotarget. 2016; 7(49):81268-81280.
PMID: 27835606
PMC: 5348391.
DOI: 10.18632/oncotarget.13222.
Netupitant, a Potent and Highly Selective NK1 Receptor Antagonist, Alleviates Acetic Acid-Induced Bladder Overactivity in Anesthetized Guinea-Pigs.
Palea S, Guilloteau V, Rekik M, Lovati E, Guerard M, Guardia M
Front Pharmacol. 2016; 7:234.
PMID: 27540361
PMC: 4972833.
DOI: 10.3389/fphar.2016.00234.
The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Munoz M, Covenas R, Esteban F, Redondo M
J Biosci. 2015; 40(2):441-63.
PMID: 25963269
DOI: 10.1007/s12038-015-9530-8.
Involvement of substance P and the NK-1 receptor in pancreatic cancer.
Munoz M, Covenas R
World J Gastroenterol. 2014; 20(9):2321-34.
PMID: 24605029
PMC: 3942835.
DOI: 10.3748/wjg.v20.i9.2321.
The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines.
Munoz M, Rosso M, Gonzalez-Ortega A, Covenas R
Cancers (Basel). 2013; 2(2):611-23.
PMID: 24281084
PMC: 3835094.
DOI: 10.3390/cancers2020611.
Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.
Li X, Ma G, Ma Q, Li W, Liu J, Han L
Mol Cancer Res. 2013; 11(3):294-302.
PMID: 23345604
PMC: 3709020.
DOI: 10.1158/1541-7786.MCR-12-0609.
The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.
Rosso M, Munoz M, Berger M
ScientificWorldJournal. 2012; 2012:381434.
PMID: 22545017
PMC: 3322385.
DOI: 10.1100/2012/381434.
The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
Munoz M, Rosso M
Invest New Drugs. 2009; 28(2):187-93.
PMID: 19148578
DOI: 10.1007/s10637-009-9218-8.
TRPV1-mediated protection against endotoxin-induced hypotension and mortality in rats.
Wang Y, Novotny M, Quaiserova-Mocko V, Swain G, Wang D
Am J Physiol Regul Integr Comp Physiol. 2008; 294(5):R1517-23.
PMID: 18337316
PMC: 2668825.
DOI: 10.1152/ajpregu.00005.2008.
NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
Munoz M, Rosso M, Aguilar F, Gonzalez-Moles M, Redondo M, Esteban F
Invest New Drugs. 2007; 26(2):111-8.
PMID: 17906845
DOI: 10.1007/s10637-007-9087-y.
Role of tachykinin NK receptors on the local and remote injuries following ischaemia and reperfusion of the superior mesenteric artery in the rat.
Souza D, Mendonca V, Castro M, Poole S, Teixeira M
Br J Pharmacol. 2002; 135(2):303-12.
PMID: 11815365
PMC: 1573137.
DOI: 10.1038/sj.bjp.0704464.
Potential of substance P antagonists as antiemetics.
Diemunsch P, Grelot L
Drugs. 2000; 60(3):533-46.
PMID: 11030465
DOI: 10.2165/00003495-200060030-00002.
Evidence for tonic activation of NK-1 receptors during the second phase of the formalin test in the Rat.
Henry J, Yashpal K, Pitcher G, Chabot J, Coderre T
J Neurosci. 1999; 19(15):6588-98.
PMID: 10414986
PMC: 6782809.
Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene.
Zimmer A, Zimmer A, Baffi J, Usdin T, Reynolds K, Konig M
Proc Natl Acad Sci U S A. 1998; 95(5):2630-5.
PMID: 9482938
PMC: 19441.
DOI: 10.1073/pnas.95.5.2630.